NG
ADPT icon

NWK Group’s Adaptive Biotechnologies ADPT Stock Holding History

NWK Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,040
Closed -$42K – 97
2021
Q1 		$42K Buy
+1,040
New +$56.3K 0.02% 112

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NWK Group's ADPT Position: Q2 2021 in Review

NWK Group sold out of Adaptive Biotechnologies (ADPT) in Q2 2021, closing a stake of 1,040 shares — an estimated $42K sold.

NWK Group first reported a position in ADPT in Q1 2021 and held it in 1 quarter. The position peaked at $42K in Q1 2021. 230 funds tracked by Wall St. Rank hold ADPT as of Q2 2021.

  • NWK Group reported no remaining Adaptive Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • NWK Group sold 1,040 Adaptive Biotechnologies shares in Q2 2021, an estimated $42K.
  • NWK Group first reported a position in Adaptive Biotechnologies in Q1 2021 and held it in 1 quarter.
  • NWK Group's Adaptive Biotechnologies position peaked at $42K in Q1 2021.
  • 230 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2021.

Based on NWK Group's 13F filing for Q2 2021, filed 16 Aug 2021.